Aptose Biosciences (TSE:APS) Sets New 1-Year Low at $0.73

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares hit a new 52-week low during trading on Monday . The company traded as low as C$0.73 and last traded at C$0.67, with a volume of 5107 shares. The stock had previously closed at C$0.71.

Aptose Biosciences Trading Down 5.6 %

The company has a market capitalization of C$12.13 million, a P/E ratio of -0.08 and a beta of 1.36. The company has a debt-to-equity ratio of 670.80, a current ratio of 0.97 and a quick ratio of 5.41. The firm has a fifty day moving average price of C$0.99 and a 200-day moving average price of C$1.69.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its earnings results on Tuesday, May 14th. The biotechnology company reported C($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of C($1.12) by C$0.14. On average, equities research analysts anticipate that Aptose Biosciences Inc. will post -0.59 earnings per share for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.